SecBot SecBot
SECBOTREPLAY Home › Report › LFWD

LFWD · Lifeward announced shareholder approval of a strategic partnership with…

Lifeward Ltd. · PRESS-RELEASE filed Mar 13, 2026 at 08:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 13, 2026 at 08:00 ET

Lifeward announced shareholder approval of a strategic partnership with Oramed Pharmaceuticals, integrating Oramed’s POD™ oral delivery technology into Lifeward’s platform while receiving potential access to up to $47 million in capital. Oramed will fund clinical development of the biotech platform, allowing Lifeward to maintain focus on its core MedTech business and path to profitability.

  • Shareholders approved the issuance of shares related to the strategic partnership with Oramed Pharmaceuticals (Nasdaq: ORMP).
  • Lifeward gains access to Oramed’s POD™ oral delivery technology for biologics, with potential applications in diabetes and other chronic diseases.
  • Oramed will fund and manage the clinical development of the POD™ platform under a trial management agreement.
  • Lifeward could receive up to $47 million in capital via equity, convertible notes, milestone payments, and warrants from Oramed and another investor.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access